Danaher Corporation (DHR)vsFonar Corporation (FONR)
DHR
Danaher Corporation
$184.30
-0.38%
HEALTHCARE · Cap: $117.48B
FONR
Fonar Corporation
$19.09
-0.10%
HEALTHCARE · Cap: $120.20M
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 23422% more annual revenue ($24.78B vs $105.34M). DHR leads profitability with a 14.9% profit margin vs 6.3%. FONR trades at a lower P/E of 19.1x. DHR earns a higher WallStSmart Score of 58/100 (C).
DHR
Buy58
out of 100
Grade: C
FONR
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-60.8%
Fair Value
$114.63
Current Price
$184.30
$69.67 premium
Margin of Safety
-26.8%
Fair Value
$14.65
Current Price
$19.09
$4.44 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Generating 1.1B in free cash flow
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
3.7% revenue growth
ROE of 7.0% — below average capital efficiency
Smaller company, higher risk/reward
ROE of 5.5% — below average capital efficiency
6.3% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DHR
The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : FONR
The strongest argument for FONR centers on Price/Book, Altman Z-Score, Debt/Equity.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : FONR
The primary concerns for FONR are Market Cap, Return on Equity, Profit Margin.
Key Dynamics to Monitor
FONR carries more volatility with a beta of 0.95 — expect wider price swings.
DHR is growing revenue faster at 3.7% — sustainability is the question.
DHR generates stronger free cash flow (1.1B), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
DHR scores higher overall (58/100 vs 38/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Fonar Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
FONAR Corporation is engaged in the research, development, production, and marketing of Magnetic Resonance Imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company is headquartered in Melville, New York.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?